publication . Article . Other literature type . 2018

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study

Harris, William S.; Tintle, Nathan L.; Etherton, Mark R.; Vasan, Ramachandran S.;
  • Published: 01 Mar 2018
  • Publisher: Elsevier BV
Abstract
BACKGROUND: The extent to which omega-3 fatty acid status is related to risk for death from any cause and for incident cardiovascular disease (CVD) remains controversial. OBJECTIVE: To examine these associations in the Framingham Heart Study. DESIGN: Prospective and observational. SETTING: Framingham Heart Study Offspring cohort. MEASUREMENTS: The exposure marker was red blood cell levels of eicosapentaenoic and docosahexaenoic acids (the Omega-3 Index) measured at baseline. Outcomes included mortality (total, CVD, cancer, and other) and total CVD events in participants free of CVD at baseline. Follow-up was for a median of 7.3 years. Cox proportional hazards mo...
Subjects
free text keywords: Article, Epidemiology, Prospective cohort study, Eicosapentaenoic acid, Docosahexaenoic acid, Omega-3 fatty acids, Internal Medicine, Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Proportional hazards model, Offspring, medicine.medical_specialty, medicine, Cohort, business.industry, business, Diabetes mellitus, medicine.disease, Endocrinology, Framingham Heart Study
Related Organizations
Funded by
NIH| Red Blood Cell Fatty Acid Biomarkers and Cardiovascular Disease Risk
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01HL089590-05
  • Funding stream: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
,
NIH| THE FRAMINGHAM HEART STUDY-268025195
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: N01HC025195-005
  • Funding stream: DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS
67 references, page 1 of 5

1.Mozaffarian D Lemaitre RN King IB Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study Ann Intern Med 2013 158 515–525 23546563 [OpenAIRE] [PubMed]

2.Pottala JV Garg S Cohen BE Whooley MA Harris WS Blood eicosapentaenoic and d ocosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: The Heart and Soul Study Circ Cardiovasc Qual Outcomes 2010 3 406–412 20551373 [OpenAIRE] [PubMed]

3.Harris WS von Schacky C The Omega-3 Index: a new risk factor for death from coronary heart disease?Prev Med 2004 39 212–220 15208005 [PubMed]

4.Harris WS The Omega-3 Index: from biomarker to risk marker to risk factor Curr Atheroscler Rep 2009 11 411–417 19852881 [PubMed]

5.Farzaneh-Far R Lin J Epel ES Harris WS Blackburn EH Whooley MA Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease JAMA 2010 303 250–257 20085953 [OpenAIRE] [PubMed]

6.Marchioli R Barzi F Bomba E Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione Circulation 2002 105 1897–1903 11997274 [OpenAIRE] [PubMed]

7.Investigators G-H Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 2008 372 1223–1230 18757090 [OpenAIRE] [PubMed]

8.Rauch B Schiele R Schneider S Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study Cardiovasc Drugs Ther 2010 20 365–375

9.Roncaglioni MC Tombesi M Avanzini F n-3 fatty acids in patients with multiple cardiovascular risk factors N Engl J Med 2013 368 1800–1808 23656645 [PubMed]

Galan, P, Kesse-Guyot, E, Czernichow, S, Briancon, S, Blacher, J, Hercberg, S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010; 341: c6273 [OpenAIRE] [PubMed]

11.Bosch J Gerstein HC Dagenais GR n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 2012 367 309–318 22686415 [PubMed]

12.Eussen SR Geleijnse JM Giltay EJ Rompelberg CJ Klungel OH Kromhout D Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction Eur Heart J 2012 33 1582–1588 22301766 [OpenAIRE] [PubMed]

13.Harris WS Are n-3 fatty acids still cardioprotective?Curr Opin Clin Nutr Metab Care 2013 16 141–149 23196817 [PubMed]

14.Deckelbaum RJ Calder PC Different outcomes for omega-3 heart trials: why?Curr Opin Clin Nutr Metab Care 2012 15 97–98 22186355 [PubMed]

15.Kannel WB Feinleib M McNamara PM Garrison RJ Castelli WP An investigation of coronary heart disease in families The Framingham offspring study Am J Epidemiol 1979 110 281–290 474565 [PubMed]

67 references, page 1 of 5
Abstract
BACKGROUND: The extent to which omega-3 fatty acid status is related to risk for death from any cause and for incident cardiovascular disease (CVD) remains controversial. OBJECTIVE: To examine these associations in the Framingham Heart Study. DESIGN: Prospective and observational. SETTING: Framingham Heart Study Offspring cohort. MEASUREMENTS: The exposure marker was red blood cell levels of eicosapentaenoic and docosahexaenoic acids (the Omega-3 Index) measured at baseline. Outcomes included mortality (total, CVD, cancer, and other) and total CVD events in participants free of CVD at baseline. Follow-up was for a median of 7.3 years. Cox proportional hazards mo...
Subjects
free text keywords: Article, Epidemiology, Prospective cohort study, Eicosapentaenoic acid, Docosahexaenoic acid, Omega-3 fatty acids, Internal Medicine, Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Proportional hazards model, Offspring, medicine.medical_specialty, medicine, Cohort, business.industry, business, Diabetes mellitus, medicine.disease, Endocrinology, Framingham Heart Study
Related Organizations
Funded by
NIH| Red Blood Cell Fatty Acid Biomarkers and Cardiovascular Disease Risk
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01HL089590-05
  • Funding stream: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
,
NIH| THE FRAMINGHAM HEART STUDY-268025195
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: N01HC025195-005
  • Funding stream: DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS
67 references, page 1 of 5

1.Mozaffarian D Lemaitre RN King IB Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study Ann Intern Med 2013 158 515–525 23546563 [OpenAIRE] [PubMed]

2.Pottala JV Garg S Cohen BE Whooley MA Harris WS Blood eicosapentaenoic and d ocosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: The Heart and Soul Study Circ Cardiovasc Qual Outcomes 2010 3 406–412 20551373 [OpenAIRE] [PubMed]

3.Harris WS von Schacky C The Omega-3 Index: a new risk factor for death from coronary heart disease?Prev Med 2004 39 212–220 15208005 [PubMed]

4.Harris WS The Omega-3 Index: from biomarker to risk marker to risk factor Curr Atheroscler Rep 2009 11 411–417 19852881 [PubMed]

5.Farzaneh-Far R Lin J Epel ES Harris WS Blackburn EH Whooley MA Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease JAMA 2010 303 250–257 20085953 [OpenAIRE] [PubMed]

6.Marchioli R Barzi F Bomba E Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione Circulation 2002 105 1897–1903 11997274 [OpenAIRE] [PubMed]

7.Investigators G-H Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 2008 372 1223–1230 18757090 [OpenAIRE] [PubMed]

8.Rauch B Schiele R Schneider S Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study Cardiovasc Drugs Ther 2010 20 365–375

9.Roncaglioni MC Tombesi M Avanzini F n-3 fatty acids in patients with multiple cardiovascular risk factors N Engl J Med 2013 368 1800–1808 23656645 [PubMed]

Galan, P, Kesse-Guyot, E, Czernichow, S, Briancon, S, Blacher, J, Hercberg, S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010; 341: c6273 [OpenAIRE] [PubMed]

11.Bosch J Gerstein HC Dagenais GR n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 2012 367 309–318 22686415 [PubMed]

12.Eussen SR Geleijnse JM Giltay EJ Rompelberg CJ Klungel OH Kromhout D Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction Eur Heart J 2012 33 1582–1588 22301766 [OpenAIRE] [PubMed]

13.Harris WS Are n-3 fatty acids still cardioprotective?Curr Opin Clin Nutr Metab Care 2013 16 141–149 23196817 [PubMed]

14.Deckelbaum RJ Calder PC Different outcomes for omega-3 heart trials: why?Curr Opin Clin Nutr Metab Care 2012 15 97–98 22186355 [PubMed]

15.Kannel WB Feinleib M McNamara PM Garrison RJ Castelli WP An investigation of coronary heart disease in families The Framingham offspring study Am J Epidemiol 1979 110 281–290 474565 [PubMed]

67 references, page 1 of 5
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2018

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study

Harris, William S.; Tintle, Nathan L.; Etherton, Mark R.; Vasan, Ramachandran S.;